Skip to main content
SpringerLink
Log in

Allogeneic Transplantation for CML

  • Chapter
Book cover Myeloproliferative Disorders

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 947 Accesses

Abstract

The management of CML has changed dramatically over the past 5–7 years. The development of the specific tyrosine kinase inhibitor, imatinib, has resulted in incidences of cytogenetic and molecular response that far exceed those achieved with interferon. The median duration of survival is predicted to increase and the role of allogeneic transplantation has correspondingly decreased. However, the technology of allografting has also progressed in that developments in molecular typing methodology and in the management of infection have resulted in an improvement in the outcome of unrelated transplants. The imatinib era has coincided with the development of reduced intensity conditioning regimens and early results suggest that this is an effective strategy in CML associated with low transplant-related mortality. This chapter summarizes the data on the prognostic factors for both disease- and transplant-related outcomes and outlines the current indications for allogeneic transplant in CML. These indications for allografting will continue to evolve. Although allogeneic transplant is no longer the initial therapy in the majority of patients, it remains the strategy with the highest probability of achieving a molecular remission and curing the disease. As such it will continue to play a role in the management of CML.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Avery S, Nadal E, Marin D, Olavarria E, Kaeda J, Vulliamy T, Brito Babapulle F, Goldman JM, Apperley JF (2004) Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res 28(Suppl 1):75–77

    Article  Google Scholar 

  • Baccarani M, Saglio G et al (2006) Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood

    Google Scholar 

  • Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, Schaefer UW (1995) Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981–2990

    PubMed  CAS  Google Scholar 

  • Bornhauser M, Kiehl M, Siegert W, Schetelig J, Hertenstein B, Martin H, Schwerdtfeger R, Sayer HG, Runde V, Kroger N, Theuser C, Ehninger G (2001) Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol 115:119–124

    Article  PubMed  CAS  Google Scholar 

  • Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW (2003) Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941–1949

    Article  PubMed  CAS  Google Scholar 

  • Clift RA, Storb R (1996) Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 17(Suppl 3):1–3

    Google Scholar 

  • Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ, Storb R, Thomas ED (1999) Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 94:3960–3962

    PubMed  CAS  Google Scholar 

  • Costello RT, Kirk J, Gabert J (1996) Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma 20:239–243

    PubMed  CAS  Google Scholar 

  • Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106:2969–2976

    Article  PubMed  CAS  Google Scholar 

  • Das M, Saikia TK, Advani SH, Parikh PM, Tawde S (2003) Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 32:125–129

    Article  PubMed  CAS  Google Scholar 

  • Davies SM, DeFor TE, McGlave PB, Miller JS, Verfaillie CM, Wagner JE, Weisdorf DJ (2001) Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 110:339–346

    Article  PubMed  CAS  Google Scholar 

  • Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E, Cwynarski K, Olavarria E, Yong A, Apperley JF, Goldman JM (2000) Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96:2712–2716

    PubMed  CAS  Google Scholar 

  • Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boque C, Faber E, Nagler A, Pogliani E, Russell N, Volin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D (2006) The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 91:452–459

    PubMed  CAS  Google Scholar 

  • Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW (1999) The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 94:384–389

    PubMed  CAS  Google Scholar 

  • Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A, Runde V, Grosse-Wilde H, Beelen DW, Schaefer UW (2002) Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99:1130–1135

    PubMed  CAS  Google Scholar 

  • Elmaagacli AH, Peceny R, Steckel NC, Trenschel R, Ottinger H, Beelen DW (2003) Outcome of transplantation of highly purified peripheral blood CD34+ cells with T cell add-back compared to unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with 1st chronic phase CML. Bone Marrow Transplant 31(Abst):O346

    Article  Google Scholar 

  • Fischer T, Reifenrath C, Hess GR, Corsetti MT, Kreil S, Beck J, Meinhardt P, Beltrami G, Schuch B, Gschaidmeier H, Hehlmann R, Hochhaus A, Carella A, Huber C (2002) Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 16:1220–1228

    Article  PubMed  CAS  Google Scholar 

  • Gilleece M, Dazzi F (2003) Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 44:23–28

    Article  PubMed  Google Scholar 

  • Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531–4536

    PubMed  CAS  Google Scholar 

  • Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH, Klein JP, McGlave PB, Schiller G, Gale RP, Rowlings PA, Horowitz MM (2000) Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood 95:410–415

    PubMed  CAS  Google Scholar 

  • Goldman J (2001) Implications of imatinib mesylate for hematopoietic stem cell transplantation. Semin Hematol 38:28–34

    Article  PubMed  CAS  Google Scholar 

  • Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A et al (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235–2238

    PubMed  CAS  Google Scholar 

  • Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319–325

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087–1092

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J (2001a) Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J 2:363–370

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A (2001b) Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 27:899–916

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A (2004) Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 34:855–875

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C (2005) Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36:757–769

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Brand R, Apperley JF, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Niederwieser D (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An Analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 99:513–521

    Google Scholar 

  • Guglielmi C, Arcese W, Hermans J, Bacigalupo A, Bandini G, Bunjes D, Carreras E, Devergie A, Frassoni F, Goldman J, Gratwohl A, Kolb HJ, Iori AP, Niederwieser D, Prentice HG, de Witte T, Apperley J (2000) Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 95:3328–3334

    PubMed  CAS  Google Scholar 

  • Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, Schattenberg A, Kolb HJ, Ljungman P, Devergie A, Bacigalupo A, Gomez M, Michallet M, Elmaagacli A, Gratwohl A, Apperley J, Niederwieser D (2002) Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100:397–405

    Article  PubMed  CAS  Google Scholar 

  • Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J Sanders JE, Storb RF, Sullivan KM, Anasetti C (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968

    Article  PubMed  CAS  Google Scholar 

  • Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850–858

    Article  PubMed  CAS  Google Scholar 

  • Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Loffler H, Pralle H, Queisser W, Tobler A (1999) Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 94:3668–3677

    PubMed  CAS  Google Scholar 

  • Horowitz M, Rowlings P, Passweg J (1996) Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant Suppl 3: 5–6

    Google Scholar 

  • Hughes TP, Morgan GJ, Martiat P, Goldman JM (1991) Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 77:874–878

    PubMed  CAS  Google Scholar 

  • Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 349:1423–1432

    Article  PubMed  CAS  Google Scholar 

  • Hughes TP, Deininger M et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28–37

    Article  PubMed  CAS  Google Scholar 

  • Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW (2003) Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102: 2205–2212

    Article  PubMed  CAS  Google Scholar 

  • Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR (2001) Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98:1732–1738

    Article  PubMed  CAS  Google Scholar 

  • Jabbour E, Kantarjian H, O’Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J (2006) Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107:480–482

    Article  PubMed  CAS  Google Scholar 

  • Kaeda J, Szydlo RM, O’Shea D, Olavarria E, Dazzi F, Marin D, Saunders S, Khorashad JS, Cross NCP, Goldman JM, Apperley JF (2006) Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 107:4171–4176

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian HM, O’Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M (2002) Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100:1590–1595

    PubMed  CAS  Google Scholar 

  • Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM (2005) Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19:990–997

    Article  PubMed  CAS  Google Scholar 

  • Kim SE, Lee JH, Choi SJ, Kim WK, Lee JS, Sohn HJ, Kang HJ, Park S, Kim K, Kim K, Seol M, Lee YS, Lee KH (2003) Intravenous vs. oral busulfan-based conditioning therapy prior to allogeneic bone marrow transplantation — A case controlled study. Blood 102 (abstract no 2629)

    Google Scholar 

  • Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465

    PubMed  CAS  Google Scholar 

  • Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050

    PubMed  CAS  Google Scholar 

  • Lin F, van Rhee F, Goldman JM, Cross NC (1996) Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87:4473–4478

    PubMed  CAS  Google Scholar 

  • Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF, Olavarria E (2002) The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica 87:979–988

    PubMed  CAS  Google Scholar 

  • Maziarz RT, Mauro MJ (2003) Transplantation for chronic myelogenous leukemia: yes, no, maybe soAn Oregon perspective. Bone Marrow Transplant 32:459–469

    Article  PubMed  Google Scholar 

  • Medina J, Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J (2003) Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98:1905–1911

    Article  PubMed  CAS  Google Scholar 

  • Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T (1998) Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 102:768–774

    Article  PubMed  CAS  Google Scholar 

  • Morimoto A, Ogami A, Chiyonobu T, Takanashi M, Sugimoto T, Imamura T, Ishida H, Yoshihara T, Imashuku S (2004) Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate. J Pediatr Hematol Oncol 26:320–322

    Article  PubMed  Google Scholar 

  • Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Woolfrey A, Anasetti C (1998) Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 92:394–401

    PubMed  CAS  Google Scholar 

  • Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, van Rhee F, Kaeda J, Cross NC, Craddock C, Kanfer E, Apperley J, Goldman JM (2001) Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 115:569–574

    Article  PubMed  CAS  Google Scholar 

  • O’Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM (2003) Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 17:481–487

    Article  PubMed  CAS  Google Scholar 

  • Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NC, Goldman JM (2001) Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97:1560–1565

    Article  PubMed  CAS  Google Scholar 

  • Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF, Goldman JM (2002) Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 99:3861–3862

    Article  PubMed  CAS  Google Scholar 

  • Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T (2003) Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 17:1707–1712

    Article  PubMed  CAS  Google Scholar 

  • Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441–445

    Article  PubMed  CAS  Google Scholar 

  • Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA (2004) Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 125:613–620

    Article  PubMed  Google Scholar 

  • Petersdorf EW, Anasetti C, Martin PJ, Gooley T, Radich J, Malkki M, Woolfrey A, Smith A, Mickelson E, Hansen JA (2004) Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104:2976–2980

    Article  PubMed  CAS  Google Scholar 

  • Pichert G, Roy DC, Gonin R, Alyea EP, Belanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C et al (1995) Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 13:1704–1713

    PubMed  CAS  Google Scholar 

  • Preudhomme C, Wattel E, Lai JL, Henic N, Meyer L, Noel MP, Cosson A, Jouet JP, Fenaux P (1995) Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: a report on 38 consecutive cases. Leuk Lymphoma 18:265–271

    PubMed  CAS  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J (2005) Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105:2281–2286

    Article  PubMed  CAS  Google Scholar 

  • Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P et al (1995) Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85:2632–2638

    PubMed  CAS  Google Scholar 

  • Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L, Edmands S, Flowers ME, Kerkof K, Nelson R, Appelbaum FR (2001) The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood 98:1701–1707

    Article  PubMed  CAS  Google Scholar 

  • Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, Martin P, Slattery J, Sultan D, Appelbaum FR (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102:31–35

    Article  PubMed  CAS  Google Scholar 

  • Randolph SSB, Gooley TA, Warren EH, Appelbaum FR, Riddell SR (2004) Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 103:347–352

    Article  PubMed  CAS  Google Scholar 

  • Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG, Aschan J, Beelen DW, Basara N, Kumlien G, Fauser AA, Runde V (2001) No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98:1739–1745

    Article  PubMed  CAS  Google Scholar 

  • Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M, Silver SM, Ginsburg D (1992) Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 79:276–282

    PubMed  CAS  Google Scholar 

  • Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-Aguirre CH, Vela-Ojeda J, Garcia-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, Miranda E, Giralt S (2005) The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 36:1043–1047

    Article  PubMed  CAS  Google Scholar 

  • Sandmaier BM, McSweeney P, Yu C, Storb R (2000) Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol 27:78–81

    PubMed  CAS  Google Scholar 

  • Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ (2005) Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 3:1009–1015

    Article  Google Scholar 

  • Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R (1990) Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci USA 87:563–567

    Article  PubMed  CAS  Google Scholar 

  • Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR (1997) Marrow transplantation for chronic myeloid leukemia: The Influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055–3060

    PubMed  CAS  Google Scholar 

  • Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763

    PubMed  CAS  Google Scholar 

  • Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ (2003) The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant 32:897–901

    Article  PubMed  CAS  Google Scholar 

  • Sokal J, Cox E, Baccarani M, Tura S, Gomez G, Robertson J, Tso C, Braun T, Clarkson B, Cervantes F (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63:789–799

    PubMed  CAS  Google Scholar 

  • Stem Cell Trialists’ Collaborative Group (2005) Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23:5074–5087

    Article  Google Scholar 

  • Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, Leisenring W, Shulman H (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048–3054

    PubMed  CAS  Google Scholar 

  • Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, Mozziconacci MJ, Maarek O, Mossafa H, Auger N, Dastugue N, Talmant P, Van den Akker J, Leonard C, Khac FN, Mugneret F, Viguie F, Lafage-Pochitaloff M, Bastie JN, Roux GL, Nicolini F, Maloisel F, Vey N, Laurent G, Recher C, Vigier M, Yacouben Y, Giraudier S, Vernant JP, Salles B, Roussi J, Castaigne S, Leymarie V, Flandrin G, Lessard M (2004) Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18: 1340–1346

    Article  PubMed  CAS  Google Scholar 

  • Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringden O (2003) Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 101:469–472

    Article  PubMed  CAS  Google Scholar 

  • Wassmann B, Klein SA, Scheuring U, Pfeifer H, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG (2001) Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with AP CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 28:721–724

    Article  PubMed  CAS  Google Scholar 

  • Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P (2002) Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99:1971–1977

    Article  PubMed  CAS  Google Scholar 

  • Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C, Schwerdtfeger R, Kolb HJ (2004) Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 34:1083–1088

    Article  PubMed  CAS  Google Scholar 

  • Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV (2006) Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase as predictors of longer survival in patients with CML. Blood 107:205–212

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 2QQ, UK

    Charles Crawley

  2. Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA, 98109, USA

    Jerald Radich

  3. Department of Haematology Faculty of Medicine Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK

    Jane Apperley

Authors
  1. Charles Crawley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerald Radich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jane Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Crawley, C., Radich, J., Apperley, J. (2007). Allogeneic Transplantation for CML. In: Myeloproliferative Disorders. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34506-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34506-0_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34505-3

  • Online ISBN: 978-3-540-34506-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation